.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Dr. Jiri Eitler

Speaker

22/09/2022
16:40 – 16:45 3 Min. 2 Min.
Poster
PS-4-4
PARP inhibitors render otherwise resistant ovarian and breast carcinoma cells sensitive towards NK cell-mediated lysis
12. Zelltherapie und Gentherapie

Further involvements

21/09/2022
12:00 – 12:10 6 Min. 4 Min.
Abstractvortrag (Best Abstract)
VS-4-1 (Best Abstract)
CAR-mediated retargeting of NK cells overcomes tumor immune escape based on ICAM-1 downregulation
12. Zelltherapie und Gentherapie, 18. Zukunftsgebiete der Transfusionsmedizin
21/09/2022
12:30 – 12:40 6 Min. 4 Min.
Abstractvortrag
VS-4-4
Dual targeting of CAR-NK cells to PD-L1 and HER2 facilitates specific elimination of cancer cells of solid tumor origin and overcomes immune escape by antigen loss
12. Zelltherapie und Gentherapie
22/09/2022
16:40 – 16:45 3 Min. 2 Min.
Poster
PS-4-4
PARP inhibitors render otherwise resistant ovarian and breast carcinoma cells sensitive towards NK cell-mediated lysis
12. Zelltherapie und Gentherapie